AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28361739 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT moderate (1-6 g/day)
Number of subjects: 30
Study 28361739 — intervention group
Group type: COMPARATOR
Intervention: MCT low (<1 g/day)
Number of subjects: 30
Study 26518479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ω‐3 PUFA‐enriched lipid emulsion 20% infusion 7 mL/kg once a day for 2 days before surgery and postoperative day (POD) 0
Number of subjects: 40
Study 26518479 — intervention group
Group type: COMPARATOR
Intervention: Glucose 5%
Number of subjects: 40
Study 25003731 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated cartoon‐aided teaching
Number of subjects: 80
Study 25003731 — intervention group
Group type: COMPARATOR
Intervention: Oral presentation without demonstration
Number of subjects: 80
Study 22661450 — intervention group
Group type: EXPERIMENTAL
Intervention: Proadrenomedullin (ProADM) testing combined with the REA-ICU score
Number of subjects: 877
Study 22661450 — intervention group
Group type: EXPERIMENTAL
Intervention: Proadrenomedullin (ProADM) value ≥ 1.8 nmol/L or assignment to REA-ICU risk classes III-IV
Number of subjects: 877
Study 22661450 — intervention group
Group type: EXPERIMENTAL
Intervention: Proadrenomedullin (ProADM)
Number of subjects: 877
Study 22661450 — intervention group
Group type: EXPERIMENTAL
Intervention: Proadrenomedullin (ProADM) combined with REA-ICU score
Number of subjects: 877
Study 19542859 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drain (12G) placed in preperitoneal space, removed within 24 hours after operation.
Number of subjects: 929
Study 19542859 — intervention group
Group type: COMPARATOR
Intervention: No drain used during TEP repair.
Number of subjects: 929
Study 16679997 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (6%) supplementation (4 mL x kg(‐1) x 15 min(‐1))
Number of subjects: 15
Study 16679997 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 15
Study 14647983 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical parametric mapping (SPM)
Number of subjects: 24
Study 14647983 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐photon emission tomography (SPET)
Number of subjects: 24
Study 11683688 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg oral tegaserod
Number of subjects: 12
Study 11683688 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg intravenous tegaserod
Number of subjects: 12
Study 11683688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11683688 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intravenous tegaserod
Number of subjects: 12
Study 9149576 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis for pulmonary embolism
Number of subjects: 312
Study 7713201 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg beclomethasone dipropionate (BDP)
Number of subjects: 134
Study 7713201 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg fluticasone propionate (FP)
Number of subjects: 134
Study 3372274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollenex BP-850 Automatic Sphygmomanometer (standard condition)
Number of subjects: 80
Study 3372274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollenex BP-850 Automatic Sphygmomanometer (silent condition)
Number of subjects: 80
Study 3372274 — intervention group
Group type: COMPARATOR
Intervention: Hawkesley Random Zero Sphygmomanometer (comparison group)
Number of subjects: 80
Study 31642607 — intervention group
Group type: COMPARATOR
Intervention: PF-05089771 alone
Number of subjects: 25
Study 31642607 — intervention group
Group type: COMPARATOR
Intervention: PF-05089771 with pregabalin
Number of subjects: 25
Study 31642607 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 25
Study 31642607 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 25
Study 29871696 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening routine data collection and data use activities; implementation of the WHO Safe Childbirth Checklist modified for preterm birth; PRONTO simulation training and mentoring; support of quality improvement teams.
Number of subjects: 0
Study 29871696 — intervention group
Group type: COMPARATOR
Intervention: Data strengthening and introduction of the modified checklist.
Number of subjects: 0
Study 27642676 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 63
Study 27642676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 63
Study 27642676 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 63
Study 26344023 — intervention group
Group type: COMPARATOR
Intervention: 2011-2012 cohort
Number of subjects: 432
Study 26344023 — intervention group
Group type: COMPARATOR
Intervention: 1997-1998 cohort
Number of subjects: 432
Study 23238388 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin K1 cream
Number of subjects: 101
Study 23238388 — intervention group
Group type: COMPARATOR
Intervention: Historical control (no vitamin K1 cream)
Number of subjects: 101
Study 21497108 — intervention group
Group type: EXPERIMENTAL
Intervention: Left single-lung transplantation (L-SLTx)
Number of subjects: 142
Study 21497108 — intervention group
Group type: EXPERIMENTAL
Intervention: Right single-lung transplantation (R-SLTx)
Number of subjects: 142
Study 21497108 — intervention group
Group type: COMPARATOR
Intervention: Both L-SLTx and R-SLTx
Number of subjects: 142
Study 18279044 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 0
Study 15339999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (IVAA) 2000 mg
Number of subjects: 36
Study 15339999 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 36
Study 11228382 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM+BCG
Number of subjects: 3
Study 11228382 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 3
Study 11228382 — intervention group
Group type: COMPARATOR
Intervention: Vaccine diluent
Number of subjects: 3
Study 9608601 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of triazolam
Number of subjects: 12
Study 9608601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8032035 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and targets for changing lifestyle
Number of subjects: 297
Study 8032035 — intervention group
Group type: COMPARATOR
Intervention: Results only (Control)
Number of subjects: 297
Study 2531676 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Prevention Program (based on the Waterloo Smoking Program)
Number of subjects: 1013
Study 2531676 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular Risk Prevention Program (control group, based on an ad hoc program by the USL)
Number of subjects: 1013
Study 1092210 — intervention group
Group type: EXPERIMENTAL
Intervention: Alupent Syrup (metaproterenol sulfate)
Number of subjects: 23
Study 1092210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31438954 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 44818
Study 31438954 — intervention group
Group type: COMPARATOR
Intervention: Physicians' reporting
Number of subjects: 44818
Study 31438954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohen's kappa for agreement
Number of subjects: 44818
Study 28463756 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 236
Study 28463756 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 236
Study 26109992 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 37
Study 26109992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 23150709 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy including bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (6-8 cycles)
Number of subjects: 1323
Study 22066973 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine plus tramadol 5 mg/mL
Number of subjects: 61
Study 22066973 — intervention group
Group type: COMPARATOR
Intervention: 0.125% ropivacaine plus fentanyl 3 ug/mL
Number of subjects: 61
Study 19299400 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrofitting insulation
Number of subjects: 1350
Study 16944096 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month aerobic exercise programme (30 min, three times a week, 70-80% of maximal heart rate)
Number of subjects: 59
Study 16944096 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 59
Study 15614660 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical activity program
Number of subjects: 177
Study 15614660 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 177
Study 11524468 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day after initial 5 mg/day for 28 days
Number of subjects: 290
Study 11524468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 9252712 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance endocrine therapy (MET)
Number of subjects: 207
Study 9252712 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (120 mg/sqm) +/− lonidamine (600 mg/daily)
Number of subjects: 207
Study 8325946 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) 180 micrograms daily for 3 weeks, then 360 micrograms daily for 3 weeks
Number of subjects: 14
Study 8325946 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,5,3'-triiodothyroacetic acid (Triac) 1700 micrograms daily for 3 weeks, then 3400 micrograms daily for 3 weeks
Number of subjects: 14
Study 8325946 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study 3551970 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 0
Study 3551970 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 30 mg
Number of subjects: 0
Study 3551970 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (both doses)
Number of subjects: 0
Study 29998439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropren (polyprenol-containing drug)
Number of subjects: 0
Study 29998439 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 27085126 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided skiing for 12 weeks (n=22); average heart rate 72.7% of maximum
Number of subjects: 42
Study 27085126 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided skiing for 12 weeks (n=22)
Number of subjects: 42
Study 27085126 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 42
Study 24839206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept (loading dose 4.4 mg/kg followed by 2.2 mg/kg weekly, subcutaneously)
Number of subjects: 71
Study 24839206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 71
Study 24839206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 24839206 — intervention group
Group type: COMPARATOR
Intervention: Rilonacept and Placebo
Number of subjects: 71
Study 21929831 — intervention group
Group type: EXPERIMENTAL
Intervention: Face to face cognitive behaviour therapy (CBT)
Number of subjects: 0
Study 21929831 — intervention group
Group type: COMPARATOR
Intervention: Telephone cognitive behaviour therapy (CBT)
Number of subjects: 0
Study 20484618 — intervention group
Group type: EXPERIMENTAL
Intervention: Oritavancin 800 mg intravenously
Number of subjects: 240
Study 20484618 — intervention group
Group type: EXPERIMENTAL
Intervention: Oritavancin 200 mg intravenously
Number of subjects: 240
Study 20484618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 20484618 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg orally
Number of subjects: 240
Study 18359186 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) program
Number of subjects: 0
Study 18359186 — intervention group
Group type: COMPARATOR
Intervention: Non-MBSR (control group)
Number of subjects: 0
Study 16002807 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Zn supplementation
Number of subjects: 48
Study 16002807 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Zn supplementation
Number of subjects: 48
Study 16002807 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg Zn)
Number of subjects: 48
Study 12084809 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (2-2.5 mg patches/d)
Number of subjects: 67
Study 12084809 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 67
Study 12084809 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone
Number of subjects: 67
Study 10214570 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON-L
Number of subjects: 298
Study 10214570 — intervention group
Group type: COMPARATOR
Intervention: Control (no ADCON-L)
Number of subjects: 298
Study 8592310 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm with spermicide
Number of subjects: 216
Study 8592310 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm only
Number of subjects: 216
Study 8592310 — intervention group
Group type: COMPARATOR
Intervention: Spermicide only (control group)
Number of subjects: 216
Study 2775143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study 2775143 — intervention group
Group type: COMPARATOR
Intervention: Additional treatment based on the depression model
Number of subjects: 0
Study 795498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone combined with intravenous low‐molecular‐weight dextran (dextran 40)
Number of subjects: 40
Study 795498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31628894 — intervention group
Group type: EXPERIMENTAL
Intervention: Spino-cerebellar tDCS (anodal spinal tDCS with cathodal cerebellar tDCS)
Number of subjects: 37
Study 31628894 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 37
Study 28559399 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 39763
Study 28559399 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 39763
Study 28559399 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 39763
Study 28559399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimmediate responders
Number of subjects: 39763
Study 28559399 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 39763
Study 25222091 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright seated posture
Number of subjects: 74
Study 25222091 — intervention group
Group type: COMPARATOR
Intervention: Slumped seated posture
Number of subjects: 74
Study 23903527 — intervention group
Group type: EXPERIMENTAL
Intervention: Rugby League players
Number of subjects: 46
Study 23903527 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 23903527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 22165359 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist supplementary prescribing
Number of subjects: 360
Study 22165359 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist medication history only
Number of subjects: 360
Study 22165359 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 360
Study 19543909 — intervention group
Group type: EXPERIMENTAL
Intervention: SDEP
Number of subjects: 11
Study 19543909 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 11
Study 16937386 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based therapy (FBT)
Number of subjects: 0
Study 15512838 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic (5g EMLA)
Number of subjects: 10
Study 15512838 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 10
Study 10930969 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMS system
Number of subjects: 88
Study 10930969 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐report scores (Morisky)
Number of subjects: 88
Study 10930969 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet counts
Number of subjects: 88
Study 10930969 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood concentration assays
Number of subjects: 88
Study 10930969 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordothiepin:dothiepin ratio > or = 1.1
Number of subjects: 88
Study 10930969 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance
Number of subjects: 88
Study 10812314 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic community program
Number of subjects: 1573
Study 10812314 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical dependency program
Number of subjects: 1573
Study 8857135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine n‐butyl bromide 20 mg
Number of subjects: 56
Study 8857135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 1996746 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg for induction followed by 6 mg/kg/hour for maintenance
Number of subjects: 40
Study 1996746 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4 mg/kg with enflurane 1% for maintenance
Number of subjects: 40
Study 1996746 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 40
Study 1996746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Propofol and Thiopentone/Enflurane)
Number of subjects: 40
Study 6374869 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 101
Study 6374869 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal vagotomy
Number of subjects: 101
Study 6374869 — intervention group
Group type: COMPARATOR
Intervention: Simple closure
Number of subjects: 101
Study 6374869 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal and pentagastrin‐ and insulin‐stimulated acid outputs
Number of subjects: 101
Study 6374869 — intervention group
Group type: COMPARATOR
Intervention: Simple closure of perforation
Number of subjects: 101
Study 6374869 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid secretory data and serum gastrin levels
Number of subjects: 101
Study 30358536 — intervention group
Group type: COMPARATOR
Intervention: AC regimen (doxorubicine 50 mg/m2, cyclophosphamide 500 mg/m2)
Number of subjects: 93
Study 30358536 — intervention group
Group type: EXPERIMENTAL
Intervention: AC+Arglabin regimen (Arglabin 370 mg/m2 within 7 days)
Number of subjects: 93
Study 30358536 — intervention group
Group type: EXPERIMENTAL
Intervention: Arglabin as monotherapy
Number of subjects: 93
Study 30358536 — intervention group
Group type: EXPERIMENTAL
Intervention: AC+Arglabin regimen
Number of subjects: 93
Study 30358536 — intervention group
Group type: COMPARATOR
Intervention: AC regimen
Number of subjects: 93
Study 26836161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation (CS) in Subgroup 1 (MMSE_s <26)
Number of subjects: 2
Study 26836161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation (CS) in Subgroup 2 (MMSE_s ≥26)
Number of subjects: 2
Study 24252311 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT intervention
Number of subjects: 170
Study 24252311 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 170
Study 22901437 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders for medication adherence
Number of subjects: 254
Study 22901437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 254
Study 19730998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pop-up messages
Number of subjects: 251
Study 19730998 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-appraisal messages
Number of subjects: 251
Study 19730998 — intervention group
Group type: COMPARATOR
Intervention: Static messages
Number of subjects: 251
Study 19730998 — intervention group
Group type: COMPARATOR
Intervention: Control/blank messages
Number of subjects: 251
Study 17643277 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 200 microg
Number of subjects: 156
Study 17643277 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg
Number of subjects: 156
Study 17643277 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 600 microg
Number of subjects: 156
Study 17643277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 17643277 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol (200-600 microg)
Number of subjects: 156
Study 15863650 — intervention group
Group type: EXPERIMENTAL
Intervention: MSV-1 (five immunodominant antigens: TB10.4, ESAT-6, CFP-8, CFP-10, CFP-15)
Number of subjects: 0
Study 15863650 — intervention group
Group type: EXPERIMENTAL
Intervention: MSV-2 (antigens: CFP-11, CFP-21, CFP-22.5, MPT-64, CFP-31)
Number of subjects: 0
Study 15863650 — intervention group
Group type: COMPARATOR
Intervention: BCG (bacille Calmette-Guerin)
Number of subjects: 0
Study 11981144 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 microg intrathecal fentanyl
Number of subjects: 75
Study 11981144 — intervention group
Group type: COMPARATOR
Intervention: 8 microg intrathecal sufentanil
Number of subjects: 75
Study 9535147 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg adrenocorticotropin 1‐24
Number of subjects: 8
Study 9535147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7702050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux biocompatible polymethylmethacrylate membrane
Number of subjects: 8
Study 7702050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux complement-activating cuprophane membrane
Number of subjects: 8
Study 7702050 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux biocompatible polysulfone membrane
Number of subjects: 8
Study 7702050 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 8
Study 2719498 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (15 mmol/d)
Number of subjects: 47
Study 2719498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47